Compare ASRT & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASRT | BTMD |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 64.4M |
| IPO Year | 2004 | 2021 |
| Metric | ASRT | BTMD |
|---|---|---|
| Price | $13.95 | $1.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $35.00 | $2.25 |
| AVG Volume (30 Days) | 45.0K | ★ 232.8K |
| Earning Date | 03-16-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | N/A | ★ 0.74 |
| Revenue | $118,713,000.00 | ★ $192,219,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | $16.87 | $6.58 |
| P/E Ratio | ★ N/A | $2.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $1.35 |
| 52 Week High | $13.90 | $4.75 |
| Indicator | ASRT | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 72.14 | 39.34 |
| Support Level | $0.69 | N/A |
| Resistance Level | N/A | $2.79 |
| Average True Range (ATR) | 0.68 | 0.14 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 98.27 | 33.75 |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.